Her2

View All

antibody-drug-conjugates-adcs-in-lung-cancer-treatment
A Quick Review of Antibody-Drug Conjugates (ADCs) in Lung Cancer: HER2, TROP-2, HER3, MET, and CEACAM5 ADC Advancements

Lung cancer remains the leading cause of cancer-related death in the United States. The American Cancer Society estimates 238,340 people will be diagnosed with lung cancer in 2023, with non-small cell lung cancer (NSCLC) accounting for the majority of cases (roughly 80% to 85%).The treatment paradigm of antibody-dr...

Find More

depression
Sage’s drug meets phase 3; Blocking 2 key pathways help in tackling TNBC; FDA clears Paragonix; FDA gives a nod

The oral depression drug of Sage Therapeutics meets phase 3 efficacy A phase 3 trial of oral treatment of Sage Therapeutics for postpartum depression (PPD) has hit its primary endpoint. The drug, SAGE-217, showed significant improvements on a depression score and saw no fainting cases. SAGE-217 is an a...

Find More

HER2 Expression and its Dynamic Functional States

A research published in Nature recently identified some dynamic functional states in the breast cancer cells of HER2 breast cancer. The research postulates that women who have advanced oestrogen-receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, are prone to acquire a HER2...

Find More